Back2Move
Join us - Help Launch Accessible Neuro-Rehab
We’re raising $2.5M (SAFE) to advance BackToMove from pilots to broad clinical use—funding Q-sub and pivotal study toward FDA 510(k) Class II (PIX), EMR integrations, and partner deployments with 3–5 leading health systems and insurers.
Who Benefits & Why It Matters
- Built for people with limited clinic access—bringing rehab home, with feedback and support to improve adherence.
- Hands-free, camera-based therapy with engaging game mechanics.
- For clinicians & hospitals: remote monitoring plus dashboards, CPT/billing support, and EMR integration (Epic/Cerner) on the roadmap.
- For payors: better adherence and potential cost savings via continued home recovery.
What Your Support Funds & Milestones
- Clinical validation & pivotal study for evidence generation.
- Clinical dashboard & data flows aligned with existing reimbursement pathways.
- Product readiness: security, privacy, and rollout with provider partners.
- For payors: a path toward better adherence and potential cost savings through continued home recovery.
Protocol & Pilots
0-6 mo
Pivotal study
6-12 mo
Q-sub → 510(k) (PIX); EMR integrations; initial partner deployments.
12-18 mo
Evidence, Claims & Future Roadmap
- Back2Move is under development and not yet FDA-cleared; it is not intended to diagnose, treat, cure, or prevent disease until appropriate clearance is obtained.
- As studies complete, we will communicate specific outcomes (coordination, attention, adherence) only if supported by evidence and permitted by regulators.
- We plan to expand into preventive therapy modules over time - introduced only when supported by data and regulatory guidance.
- Results vary by individual; adoption and payer policies will determine real-world value.
